Trials / Active Not Recruiting
Active Not RecruitingNCT05535244
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
A Phase I/II, Open-Label, Multi-Cohort Study to Evaluate the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen-Exposed Patients With Relapsed/Refractory Multiple Myeloma
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cevostamab | Cevostamab will be administered by IV infusion in 21-day cycles. |
| DRUG | Tocilizumab | Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary. |
Timeline
- Start date
- 2022-10-17
- Primary completion
- 2027-02-26
- Completion
- 2027-02-26
- First posted
- 2022-09-10
- Last updated
- 2026-02-09
Locations
26 sites across 8 countries: United States, Australia, Belgium, France, Germany, Israel, Italy, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05535244. Inclusion in this directory is not an endorsement.